Interpretation of Serum Tryptase Levels in Mast Cell Disorders

Diagnostic Thresholds for Systemic Mastocytosis

A baseline serum tryptase > 20 ng/mL satisfies a minor diagnostic criterion for systemic mastocytosis and should prompt immediate bone‑marrow evaluation (aspiration, biopsy, immunophenotyping, and KIT D816V testing). 1
In patients with systemic mastocytosis, approximately 75 % have baseline tryptase levels exceeding 20 ng/mL, supporting its use as a screening marker. 2

Mast‑cell activation during anaphylaxis is diagnosed when the acute tryptase (sAT) exceeds (1.2 × baseline tryptase [sBT]) + 2 ng/mL. This formula accounts for individual baseline variation. 1
Peak serum tryptase after symptom onset occurs roughly 60–90 minutes (range 30–120 min); sampling outside this window may miss the maximal rise. [1][3]
The serum tryptase half‑life is about 2 hours, so levels decline rapidly after the peak. 3
Recommended sampling schedule for suspected anaphylaxis:
An increase of >20 % above baseline and an absolute rise of ≥2 ng/mL on at least two separate occasions defines mast‑cell activation syndrome in the context of systemic anaphylaxis. 2
Sensitivity of acute tryptase elevation is higher when hypotension is present (correlating with severity) and lower for isolated cutaneous reactions. 1
When samples are correctly timed, the specificity of the acute‑tryptase test exceeds 90 %. 1

Alpha‑tryptase is constitutively secreted by mast cells; levels are chronically elevated in systemic mastocytosis and hereditary alpha‑tryptasemia. 3
Beta‑tryptase is stored in granules and released during degranulation; acute spikes are characteristic of anaphylactic events. 3
Commercial ImmunoCAP FEIA assays report total tryptase, the sum of alpha‑ and beta‑forms, without distinguishing the individual contributions. 3
Anaphylaxis can occur via basophil or complement pathways without a measurable tryptase rise; a normal tryptase does not rule out anaphylaxis. 3

Intravenous fluid resuscitation during anaphylaxis dilutes circulating tryptase, potentially lowering observed concentrations; clinicians should consider hemodilution when interpreting results. 3
Post‑mortem serum tryptase levels are less reliable than antemortem samples, and beta‑tryptase may be modestly elevated after traumatic injury or myocardial infarction, confounding interpretation. 3
Samples collected <30 minutes or >6 hours after symptom onset markedly reduce assay sensitivity, increasing the risk of false‑negative results. 1

In properly timed testing, the acute‑tryptase assay demonstrates >90 % specificity for mast‑cell activation, making it a highly reliable confirmatory tool when positive. 1
The assay’s sensitivity varies with clinical presentation, reaching its highest values in cases with cardiovascular compromise (e.g., hypotension) and lowest in isolated skin manifestations. 1

Serum tryptase levels vary significantly across mastocytosis subtypes, with cutaneous mastocytosis typically showing normal or near-normal levels, indolent systemic mastocytosis showing moderately elevated levels, and advanced forms including mast cell leukemia showing markedly elevated levels 4

The National Comprehensive Cancer Network recommends that serum tryptase is elevated in the vast majority of patients with systemic mastocytosis across all subtypes, with persistently elevated serum total tryptase >20 ng/mL serving as one of the minor diagnostic criteria 4
Tryptase >20 ng/mL meets a minor diagnostic criterion for systemic mastocytosis and mandates bone marrow evaluation 4, 5

In pediatric cutaneous mastocytosis, serum tryptase is significantly elevated only in children with systemic disease 6
Among children with urticaria pigmentosa, 8 out of 20 had elevated tryptase, but none had bone marrow findings compatible with systemic mastocytosis 6
In mastocytomas, only 1 out of 6 children had elevated tryptase 6

The presence of an associated hematologic neoplasm may confound tryptase correlations, as the AHN itself may contribute to elevation of serum tryptase levels 4
AHNs are diagnosed in 71% of patients with mast cell leukemia, affecting tryptase interpretation 4

Tryptase >200 ng/mL indicates high mast cell burden requiring urgent hematology referral and possible hospitalization 5
The ratio of total tryptase to beta-tryptase can distinguish mastocytosis from acute anaphylaxis, with a ratio ≥20 suggesting systemic mastocytosis 5

A minority of patients with SM have normal tryptase levels, possibly related to the lack of alpha tryptase genes described in Caucasian populations 4, 7
Elevated serum tryptase may also occur transiently during anaphylaxis or in other myeloid malignancies and hereditary alpha-tryptasemia 4

The European Competence Network on Mastocytosis recommends bone marrow examination when serum tryptase is >15 ng/mL and/or KIT D816V mutation is detected 8, 9
A tryptase level of <15 ng/mL suggests follow-up only if clinical symptoms/signs suggest mastocytosis develop; otherwise consider alternative diagnoses 8, 9
A tryptase level of 15-20 ng/mL warrants consideration of bone marrow examination if KIT D816V mutation detected or clinical suspicion high 8, 9